WCOE: Replacing the SGR Formula, Patient Advocate Speaks at FDA, and Dr. Peter Ubel talks Patient Needs
What Caught Our Eye (WCOE) Each week, we recap the cancer policy articles, studies, and stories that caught our attention. #Medicare, replacing the SGR forumula, and the need for quality measures via @sarahkliff https://t.co/LP8CmO69gX— NCCS - National Coalition for Cancer Survivorship (@CancerAdvocacy) April 6, 2015 Shirley Mertz spoke at FDA Pt-Focused Drug ...
WCOE: Pace of FDA Drug Approvals, Redesigning Insurance Exchanges, Shared Decision Making, and Thoughts on Data Collection
What Caught Our Eye (WCOE) Each week, we recap the cancer policy articles, studies, and stories that caught our attention. Too Fast, or Too Slow? Public disagrees over pace of #FDA's new drug approvals https://t.co/gnvqJq56AH via @RAPSorg— ResearchAmerica (@ResearchAmerica) February 25, 2015 Everything I know about a good death I learned from ...
NCCS Policy Comments: FDA’s Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)
NCCS submitted comments to the Food and Drug Administration (FDA) on the Draft Guidance: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs). We support the FDA's efforts to develop a strong regulatory framework for LDTs and commend the agency for the open and transparent process it has pursued in ...
Announcing a New Blog Series: “The Imperatives for Quality Cancer Care” 20 Years Later
Read posts from the new blog series: "The Imperatives for Quality Cancer Care" 20 Years Later In 1995, NCCS published Imperatives for Quality Cancer Care: Access, Advocacy, Action, and Accountability (Imperatives), the culmination of an inclusive, community-based process. Adopted at the First National Congress on Cancer Survivorship, the Imperatives represented ...
WCOE: New IOM Report, Control Issues, Tempting Treatment Options, and Patients ‘Right to Try’ New Drugs
What Caught Our Eye (WCOE) Each week, we take a closer look at the cancer policy articles, studies, and stories that caught our attention. New IOM Report: Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risks https://t.co/neRjKfx8ma #datasharing— NASEM Health (@NASEM_Health) January 14, 2015 "Cancer survivors plagued by lack of personal control" ...
WCOE: FDA News, Medical Debt, the ACA, and Honoring Jessie Gruman
What Caught Our Eye (WCOE) Each week, we take a closer look at the cancer policy articles, studies, and stories that caught our attention. Why The FDA Panel's Nod To Sandoz's Filgrastim (Zarzio) Is Good News For Patients, by @ElaineSchattner - https://t.co/Dle8xM2G9I— Elaine Schattner MD, MA (@ESchattner) January 8, 2015 NEW ...
NCCS Policy Comments: Recommending Cancer Survivorship as a Topic for FDA Patient-Focused Drug Development Meetings
Last week, NCCS submitted comments to the U.S. Food and Drug Administration (FDA) regarding the series of patient-focused drug development meetings that have been convened and the list of disease topic meetings scheduled for 2016-2017. In 2013, FDA convened a patient-focused drug development meeting related to lung cancer and has ...
NCCS Offers Policy Comments: Strategies for Increasing Patient Participation in FDA Review Activities
The Food and Drug Administration Safety and Innovation Act (FDASIA) authorized a patient-focused drug development program, and in the years since enactment, the U.S. Food and Drug Administration (FDA) has implemented certain initiatives of the patient-focused program. In recent weeks, FDA has requested feedback regarding patient-focused activities to date and ...
WCOE: Brittany Maynard’s Death with Dignity, Election Results and the ACA, and Susan Gubar’s “Not Talking About Medical Mistakes”
What Caught Our Eye (WCOE) Each week, we take a closer look at the cancer policy articles, studies, and stories that caught our attention. "Why is it so difficult for patients and doctors to discuss surgical accidents and complications without violating professional codes of conduct and arousing fears of legal liability?" ...
Incremental Improvements Are Not Enough
Two years ago, the world lost an extraordinary person, my dear friend Dr. Brent Whitworth. He was a few days shy of his 42nd birthday when he learned of his diagnosis – stage IV kidney cancer – and he was devastated. He had surgery at a major cancer hospital and ...
